Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Breast implant "opt-out" order will detail BMS/Baxter/3M settlement.

This article was originally published in The Gray Sheet

Executive Summary

BREAST IMPLANT SETTLEMENT "OPT-OUT" ORDER, SLATED FOR JUDGE'S SIGNATURE either on Saturday, Oct. 7 or the week of Oct. 9, will advise Bristol-Myers Squibb, Baxter and 3M implant recipients of their options under a new agreement announced Oct. 2 by the U.S. District Court of Alabama. The technical purpose of the order from Judge Samuel Pointer, who is overseeing the class action settlement of breast implant product liability claims, is to free the 440,000 plaintiffs registered for the failed $4.23 bil. "global" class action settlement to pursue individual claims against manufacturers.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004812

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel